 |
|
Webinar
Industry Perceptions and Expectations: The Role of ICER as an Independent HTA
|
 |
|
| |
 |
|
July 31, 2018
|
|
| |
 |
|
11:00am – 12:00pm (EST)
|
|
|
|
| |
|
Industry Perceptions and Expectations: The Role of ICER as an Independent HTA
|
| |
|
Who has the job of leading the evaluation of pharmaceutical value and pricing? What impact will ICER have on payer decision-making? Will manufacturers begin to adjust their list prices to reflect valuations made in ICER reports? These questions and more continue to be at the heart of discussions surrounding how to gauge value in the US healthcare system.
|
| |
|
| |
|
Key Insights
|
| |
|
Only time will tell if ICER becomes the next NICE—but for now, it is a force that is here to stay and to be reckoned with. Join us as we explore:
|
| |
| - |
|
The evolution of health technology assessment in the US and possibilities for the future |
| |
| - |
|
Opinions of manufacturers and US payer stakeholders on the role of ICER in the US healthcare system, as learned through a primary research study of more than 50 participants |
| |
| - |
|
ICER methodologies and approaches to evaluation of clinical and health economic evidence |
| |
| - |
|
Ways manufacturers can begin to proactively prepare for an ICER assessment |
| |
|
|
| |
|
|
| |
Presenters:
|
|
| |
| |
 |
| |
Manpreet Sidhu, PhD, MBA
Divisional Principal and Head, Global Health Economics, ICON
|
| |
| |
 |
| |
Nathan White, CPC
Senior Vice President, Integrated Access and Outcomes Solutions, ICON
|
| |
|
|
|
| |
| |
 |
| |
Mike Pace, MBA
Senior Principal, Global Pricing and Market Access, ICON
|
| |
|
|
| |
|
|
|
|
|
|
|
|
|
